Treatment of ocular disease

• US 20030018044A1
• Filed: 09/19/2002
• Published: 01/23/2003
• Est. Priority Date: 02/18/2000
• Status: Abandoned Application

• Current Assignee: Astellas Pharma Incorporated
• Original Assignee: Astellas Pharma Incorporated
• Inventors: Peyman, Gholam A.
• Application Number:
  US10/247,220
• Publication Number:
  US 20030018044A1
• Time in Patent Office: Days
• US Class Current: 514/291
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

A formulation to treat ocular disease such as dry eye disease, as well as other diseases, is disclosed. Tacrolimus is administered intraocularly, such as topically or by injection. For topical administration, an amount of about 1 ng to 10 μg may be formulated in an aqueous based cream that may be applied at bedtime or throughout the day. For injection, a dose of about 20-1000 μg/ml is used. Tacrolimus may also be administered in milligram quantities as a surgical implant contained in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

Claims

1. A method to treat a diseased eye in a patient comprising intraocularly administering to the patient a composition consisting essentially of tacrolimus in a pharmaceutically acceptable formulation and in an amount effective to treat the diseased eye without substantial toxicity to the patient.

2. The method of claim 1 to treat a disease selected from the group consisting of an age related disease, an inflammatory disease, a degenerative disease, and combinations thereof.

3. The method of claim 1 to treat a disease selected from the group consisting of dry eye disease, scleritis, neuritis, papillitis, uveitis, retinopathy, retinitis pigmentosa, macular degeneration, Behcet'"'"'s syndrome, toxoplasmosis, Birdshot choroidopathy, histoplasmosis, pars planitis, sarcoidosis, sympathetic ophthalmia, serpiginous choroidopathy, diffuse pigment epitheliopathy, Vogt-Koyanagi syndrome, polyarteritis nodosa, and juvenile rheumatic arthritis.

4. The method of claim 1 wherein the composition is administered topically to the eye.

5. The method of claim 4 wherein the composition is administered as drop, a cream, or a gel.

6. The method of claim 1 wherein the composition is injected intraocularly.

7. The method of claim 1 wherein the composition is administered by retrobulbar, intravitreal, intraretinal, or subconjunctival injection.

8. The method of claim 1 wherein the composition is implanted intraocularly.

9. The method of claim 1 wherein the composition is implanted on the sclera.

10. The method of claim 1 wherein the composition is in a sustained release matrix implanted intraocularly.

11. The method of claim 10 wherein the matrix is sutured to the sclera.

12. The method of claim 1 wherein the composition contains Cyclosporin A.

13. The method of claim 1 wherein the composition is administered at a dose up to 250 μ

g tacrolimus.

14. The method of claim 7 wherein injection is subconjuctival at a dose in the range of about 1 ng/ml to about 500 μ

g/ml, intravitreal at a dose in the range of about 1 μ

g/0.1 ml to about 1000 μ

g/0.1 ml, retrobulbar at a dose in the range of about 20 μ

g/ml to about 1000 μ

g/ml, or subretinal at a dose in the range of about 1 μ

g/0.1 ml to about 100 μ

g/0.1 ml.

15. The method of claim 7 wherein injection is intravitreal at a dose of about 50 μ

g/0.1 ml.

17. The method of claim 16 to treat a disease selected from the group consisting of an age related disease, an inflammatory disease, a degenerative disease, and combinations thereof.

18. The method of claim 16 to treat a disease selected from the group consisting of dry eye disease, scleritis, neuritis, papillitis, uveitis, retinopathy, retinitis pigmentosa, macular degeneration, Behcet'"'"'s syndrome, toxoplasmosis, Birdshot choroidopathy, histoplasmosis, pars planitis, sarcoidosis, sympathetic ophthalmia, serpiginous choroidopathy, diffuse pigment epitheliopathy, Vogt-Koyanagi syndrome, polyarteritis nodosa, and juvenile rheumatic arthritis.

19. The method of claim 16 wherein the composition is administered topically to the eye.

20. The method of claim 16 wherein the composition is injected intraocularly.

21. The method of claim 20 wherein the composition is administered by subconjuctival injection at a dose in the range of about 1 ng/ml to about 500 μ

g/ml, intravitreal injection at a dose in the range of about 1 μ

g/0.1 ml to about 1000 μ

g/0.1 ml, retrobulbar injection at a dose in the range of about 20 μ

g/ml to about 1000 μ

g/ml, or subretinal injection at a dose in the range of about 1 μ

g/0.1 ml to about 100 μ

g/0.1 ml.

22. The method of claim 16 wherein the composition is implanted intraocularly.

23. The method of claim 22 wherein the composition is in a sustained release matrix implanted intraocularly.

24. The method of claim 16 wherein the composition contains Cyclosporin A.

26. The composition of claim 25 formulated as a cream with tacrolimus in an amount ranging from about 1 ng to about 10 μ

g.

27. The composition of claim 25 formulated as an injectable with tacrolimus in the range of about 1 ng/ml to about 500 μ

g/ml for subconjuctival injection, about 1 μ

g/0.1 ml to about 1000 μ

g/0.1 ml for intravitreal injection, about 20 μ

g/ml to about 1000 μ

g/ml for retrobular injection, and about 1 μ

g/0.1 ml to about 100 μ

g/0.1 ml for subretinal injection.

28. The composition of claim 25 wherein tacrolimus is in or on a physiologically compatible inert matrix.

29. The composition of claim 28 wherein the matrix comprises a substance selected from the group consisting of lipid, polyvinyl alcohol, polyvinyl acetate, polycaprolactone, poly(glycolic)acid, poly(lactic)acid, and combinations thereof.

30. The composition of claim 28 wherein the matrix sustainedly releases tacrolimus.

16. A method to treat a diseased eye in a patient comprising intraocularly administering to the patient a composition consisting essentially of tacrolimus in a pharmaceutically acceptable formulation and in an amount effective to treat the diseased eye.

25. A therapeutic composition for treating a diseased eye consisting essentially of tacrolimus in a physiologically acceptable intraocular formulation and in an amount effective to treat the diseased eye without substantial toxicity to the eye.